Acarbose extends lifespan robustly in male mice, but the mechanistic basis for its sex-specific benefits remains unclear. This hypothesis proposes that acarbose-induced gut microbiome restructuring enhances portal butyrate production, which subsequently upregulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and cortex, driving neuroprotective effects that mediate lifespan extension. Critically, this pathway is sex-dimorphic due to estrogen receptor beta (ERβ)-mediated suppression of BDNF transcription in females, explaining the male-biased longevity response.

Mechanistic Rationale

Acarbose inhibits alpha-glucosidase, diverting undigested carbohydrates to the distal gut where they fuel butyrate-producing Firmicutes [https://pmc.ncbi.nlm.nih.gov/articles/PMC9286917/]. Butyrate, a histone deacetylase (HDAC) inhibitor, can cross the blood-brain barrier and epigenetically enhance BDNF promoter activity. BDNF activation in the central nervous system promotes neuronal survival, synaptic plasticity, and autophagy—key processes in aging. The strong synergy between acarbose and rapamycin [https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs-of-2025] may stem from rapamycin's mTOR inhibition potentiating BDNF-induced autophagy, creating a compounded proteostatic benefit.

The sex disparity likely arises from hormonal modulation of BDNF signaling. Estrogen, via ERβ, represses BDNF transcription in females, whereas testosterone in males may amplify it. This aligns with the pronounced lifespan effects in male mice [https://www.gowinglife.com/lifespan-extension-is-possible-and-these-drugs-prove-it/] and suggests that acarbose's benefits are gated by sex steroid receptors. Furthermore, butyrate's reduction of systemic inflammation [https://pmc.ncbi.nlm.nih.gov/articles/PMC9286917/] may lower microglial activation, preserving BDNF function in aging brains.

Testable Predictions

This hypothesis generates several falsifiable predictions:

• BDNF Dependency: Acarbose-treated male mice should show elevated hippocampal BDNF levels compared to controls; pharmacological BDNF blockade (e.g., via anti-TrkB antibodies) should abolish lifespan extension.
• Butyrate Causality: Fecal transplants from acarbose-fed donors into germ-free mice should increase host BDNF expression and extend lifespan, but not if butyrate synthesis is inhibited (e.g., via targeted antibiotics against butyrate-producing bacteria).
• Sex Reversal: Ovariectomized female mice or males administered estrogen receptor antagonists should exhibit amplified acarbose-induced lifespan extension, while testosterone-depleted males show blunted effects.
• Combination Synergy: Rapamycin's synergy with acarbose should correlate with enhanced BDNF-driven autophagy markers (e.g., LC3-II flux) in neural tissues.

Implications and Open Questions

If validated, this gut-brain axis mechanism would reframe acarbose as a neurocentric longevity intervention, with microbiome changes as a causal lever. It also raises questions about human translation: do prediabetic individuals on acarbose [https://pmc.ncbi.nlm.nih.gov/articles/PMC5380489/] show BDNF modulation, and does this correlate with cognitive decline rates? The dose-dependent microbiome shifts [https://pubmed.ncbi.nlm.nih.gov/30728281/] could be optimized to maximize butyrate yield for BDNF induction, potentially through diet co-interventions.

Ultimately, this model challenges the view that acarbose's benefits are purely metabolic, positioning BDNF as a central mediator and offering a sex-specific framework for targeting aging pathways.